Physician profile
Randall Fan
NPI 1609029750
$1,449.13
in general payments reported to CMS, 2019-2025
14 companies · $559 in 2025
The $559 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.95 · 2023: $509 · 2024: $319 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,370 · Education: $17.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.01 |
| Education | $17.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $342.13 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $271.12 | 2023-2025 | Entyvio |
| Janssen Biotech, INC. | $203.07 | 2023 | Stelara, Simponi, Remicade |
| Abbvie INC. | $202.64 | 2024-2025 | |
| Celltrion USA INC. | $94.24 | 2023-2025 | Vegzelma, Yuflyma |
| Merck Sharp & Dohme LLC | $75.16 | 2023-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $53.57 | 2023 | Dupixent |
| Phathom Pharmaceuticals, INC. | $30.11 | 2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.71 | 2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $28.99 | 2024 | |
| Ardelyx, INC. | $23.30 | 2025 | Ibsrela |
| Genzyme Corporation | $17.96 | 2023 | |
| Qol Medical, LLC | $15.18 | 2025 | Sucraid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.